Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction Treated With Percutaneous Coronary Intervention - The Dan-DAPT Trial
Design: The Dan-DAPT trial include high bleeding risk patients with heart attacks from Danish hospitals (Rigshospitalet, Aarhus, Odense, Aalborg, Roskilde, and Gentofte hospital) and randomize them to standard-of-care or shorter and individualized antithrombotic therapy based on responsiveness to clopidogrel after genetic testing.
• MI caused by atherothrombotic CAD (Type 1 MI) according to The Fourth Universal Definition of MI, which has been treated with PCI with contemporary drug-eluting stents. This definition of type 1 MI requires the detection of a rise and/or fall of cardiac troponin values with at least one value \>99th percentile and at least one of the following criteria assessed by the treating physician:
‣ symptoms indicating acute myocardial ischemia
⁃ new ischemic changes on the electrocardiogram
⁃ development of pathological Q-waves
⁃ imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic etiology
⁃ visible coronary thrombus by angiography
• PRECISE-DAPT score ≥25
• Age ≥18 years